Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Cutaneous lymphomas (CL) are the second most common extranodal non-Hodgkin’s lymphomas. Their incidence is estimated at 1/100 000 yearly. Primary CL develop by definition in the skin and remain confined to the skin for a long period of time, while secondary CL reflect cutaneous spread from disseminated primary nodal or extranodal lymphomas. Primary CL include a wide spectrum of clinically and h...

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Primary cutaneous lymphomas (PCLs) are defined as non-Hodgkin lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. After the gastrointestinal lymphomas, PCLs are the second most common group of extranodal non-Hodgkin lymphomas with an estimated annual incidence of 1/100 000. PCL must be distinguished from nodal or systemic malignant lymphomas i...

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up B. Glimelius & J. Oliveira On behalf of the ESMO Guidelines Working Group* Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala and Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; Service of Medical Oncology, Portuguese Institute of Oncology, Lisb...

Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Immunohistochemistry should be applied in poorly differentiated cases to exclude chemosensitive and potentially curable tumors (i.e. lymphomas and germ cell tumors). If diagnosis is adenocarcinoma, immunostaining for prostate-specific antigen (PSA) in male patients and for estrogen and progesterone receptors in females with axillary node metastases is advisable to rule out hormone-sensitive tum...